October 17, 2019
FDA reviews Foamix’s NDA for minocycline topical foam for Rosacea
The FDA has accepted for review Foamix’s New Drug Application (NDA) for FMX103 (minocycline topical foam 1.5%) topical foam, for the treatment of moderate-to-severe papulopustular rosacea in adults.
